• 

  Small Molecule Immunomodulators – H1 2021

  By Christian Gampe While biologic drugs currently dominate in immunology by sales, small molecule immunomodulators (SMIMs) are making a comeback fueled by better understanding of intracellular signaling pathways and new hit finding technologies. SMIMs can be grouped into two categories: those that engage large molecule (LM) targets in a new way, and those that engage targets that…

• 

  2019 Biotech IPOs – Biologic Drug R&D

  Of the 2019 biotech IPOs on the major US exchanges, there were 24 companies focused on developing non-small molecule drugs, about the same number as those developing small molecule drugs. Here’s a list of the companies (by market cap at IPO) along with a short summary of the key concepts for each company’s main programs.…

• 

  2019 Biotech IPOs – Small Molecule R&D

  Of the 2019 biotech IPOs on the major US exchanges, 25 companies are focused on discovering and developing small molecule drugs. Here’s a list of the companies (by market cap at IPO, top to bottom) along with the main mechanisms of action of the lead molecules and other publicly disclosed targets. The largest company by…

• 

  Pd-Couplings Cheat Sheet

  There are catalysis geniuses (looking at you, process chemists!) and then there are those of us just looking to put compounds in vials.  Here are the simplest conditions that’ll get you what you want 90% of the time.  Beyond that you’ll need to ask a guru like Nick White or Malcolm Huestis. Hope this table…